Liver Injury
Q&A: Prenatal chemical exposure linked to liver injury in mothers, children 10 years later
Exposure to environmental chemicals during pregnancy may increase the risk for liver injury and steatosis in children and mothers, which could be mitigated by higher folic acid supplementation, according to a study in Journal of Hepatology.
FDA adds boxed warning to hot flash drug Veozah due to liver injury risk
The FDA added a boxed warning to highlight known risk for rare but serious liver injury associated with the use of fezolinetant, a nonhormonal medication indicated for treating menopausal hot flashes, according to an agency press release.
FDA: Ocaliva still linked to ‘serious liver injury’ in PBC, even without cirrhosis
The FDA has issued a safety alert warning that obeticholic acid carries an increased risk for “serious liver injury” among patients with primary biliary cholangitis, even those without advanced cirrhosis.
Livdelzi reduces cholestatic, liver injury markers in patients with PBC and cirrhosis
SAN DIEGO — Livdelzi appeared safe and well-tolerated and reduced markers of cholestasis and liver injury in patients with primary biliary cholangitis, including those with compensated cirrhosis, according to a presenter.
FDA lifts clinical hold on two trials assessing covalent menin inhibitor for diabetes
The FDA has lifted a clinical hold on two trials assessing an investigational treatment for people with type 1 and type 2 diabetes, Biomea Fusion announced.
FDA warns of potential liver injury with Veozah for menopausal hot flashes
The FDA issued a warning that use of fezolinetant, a nonhormonal medication indicated for treating menopausal hot flashes, can cause rare but serious liver injury, according to an agency press release.
Nearly 15.6 million Americans using botanical supplements may be at risk for liver injury
Researchers estimated that nearly 15.6 million Americans consumed at least one potentially hepatotoxic botanical product in the past 30 days, similar to usage reports for simvastatin and NSAIDS.
Bariatric surgery associated with lower mortality, health care cost in patients with MASLD
WASHINGTON — Bariatric surgery was associated with improved clinical outcomes and more cost-effective health care resource utilization among patients with metabolic dysfunction-associated steatotic liver disease, according to data.
FDA approves Livmarli for pruritus in progressive familial intrahepatic cholestasis
The FDA has approved Mirum Pharmaceuticals’ Livmarli oral solution for treatment of cholestatic pruritus in patients aged 5 years and older with progressive familial intrahepatic cholestasis, according to a company release.
Liver transplantation using COVID-19 positive donors may be safe option to expand access
BOSTON — Researchers reported similar patient and allograft survival 1 year after liver transplantation between COVID-19 positive and negative donors, showing potential for expanding organ access, according to data at The Liver Meeting.